The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11111 malaria professionals are enjoying the free benefits of MalariaWorld today

vaccine

Baseline Asymptomatic Malaria Infection and Immunogenicity of rVSVdeltaG-ZEBOV-GP Vaccine: The Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE)

May 25, 2021 - 15:01 -- Open Access
Author(s): 
Mahon BE, Simon J, Widdowson MA, Samai M, Rogier E, Legardy-Williams J, Liu K, Schiffer J, Lange J, DeByle C, Pinner R, Schuchat A, Slutsker L, Goldstein S
Reference: 
J Infect Dis. 2021 May 20:jiab243

The effect of malaria infection on rVSVΔG-ZEBOV-GP (ERVEBO®) immunogenicity is unknown.

Not Open Access | Meeting report: WHO consultation on malaria vaccine development, Geneva, 15-16 July 2019

May 25, 2021 - 14:57 -- NOT Open Access
Author(s): 
Vekemans J, Schellenberg D, Benns S, O'Brien K, Alonso P
Reference: 
Vaccine. 2021 May 21;39(22):2907-2916

Considerable progress has been made in malaria control in the last two decades, but progress has stalled in the last few years. New tools are needed to achieve public health goals in malaria control and elimination. A first generation vaccine, RTS,S/AS01, is currently being evaluated as it undergoes pilot implementation through routine health systems in parts of three African countries.

NOT Open Access | Plasmodium vivax vaccine candidate MSP1 displays conserved B-cell epitope despite high genetic diversity

May 25, 2021 - 14:54 -- NOT Open Access
Author(s): 
Ghoshal S, Kanjilal SD, Sengupta S
Reference: 
Infect Genet Evol. 2021 May 19:104929

The polymorphic nature of merozoite surface protein 1(MSP1) raises doubts whether it may serve as a vaccine target against Plasmodium vivax malaria. This study analyses the impact of genetic variability on the epitope organization of different Pvmsp1 blocks. Ten blood samples collected from P. vivax infected malaria patients from West Bengal, India were used to analyze sequence and antigenic diversities of block 2 region of Pvmsp1.

A guide to investigating immune responses elicited by whole-sporozoite pre-erythrocytic vaccines against malaria

May 18, 2021 - 13:31 -- Open Access
Author(s): 
Moita D, Nunes-Cabaço H, Mendes AM, Prudêncio M
Reference: 
FEBS J. 2021 May 16

In the last few decades, considerable efforts have been made towards the development of efficient vaccines against malaria. Whole-sporozoite (Wsp) vaccines, which induce efficient immune responses against the pre-erythrocytic (PE) stages (sporozoites and liver forms) of Plasmodium parasites, the causative agents of malaria, are among the most promising immunization strategies tested until present.

Some lessons for malaria from the Global Polio Eradication Initiative

May 6, 2021 - 07:21 -- Open Access
Author(s): 
Matiana González-Silva and N. Regina Rabinovich
Reference: 
Malaria Journal 2021 20:210, 1 May 2021

The Global Polio Eradication Initiative (GPEI) was launched in 1988 with the aim of completely clearing wild polio viruses by 2000. More than three decades later, the goal has not been achieved, although spectacular advances have been made, with wild polio virus reported in only 2 countries in 2019. In spite of such progress, novel challenges have been added to the equation, most importantly outbreaks of vaccine-derived polio cases resulting from reversion to neurovirulence of attenuated vaccine virus, and insufficient coverage of vaccination.

Genomic analysis of host gene responses to cerebral Plasmodium falciparum malaria

May 5, 2021 - 11:23 -- Open Access
Author(s): 
Li K, Wang H, Zhang HF, Zhao XX, Lai YJ, Liu FF
Reference: 
Immun Inflamm Dis. 2021 May 4

A vaccine for malaria is urgently required but no vaccine has yet shown satisfactory protective efficacy especially for Plasmodium falciparum. P. falciparum infection can progress to cerebral malaria (CM), a neurological syndrome with exceedingly high mortality. Designing effective P. falciparum vaccines require more understanding of the protective immune response while the host immune response to CM and the mechanisms are still elusive. Here, we aim to identify host gene responses to CM and host gene networks associated with CM pathogenesis.

NOT Open Access | Malaria vaccine achieves striking early success

May 5, 2021 - 08:16 -- NOT Open Access
Author(s): 
Wadman M
Reference: 
Science. 2021 Apr 30;372(6541):448


After decades of disappointing results, new findings have revived hopes for an effective vaccine against malaria, which kills some 400,000 people every year, most of them children. An experimental vaccine that targets the most dangerous form of the malaria parasite was found to have an efficacy of 71% to 77% after 1 year. The results come from a trial of a vaccine developed by researchers at the University of Oxford involving 450 toddlers in Burkina Faso.

NOT Open Access | Immunoinformatics approach for multi-epitope vaccine design against P. falciparum malaria

April 29, 2021 - 07:23 -- NOT Open Access
Author(s): 
Maharaj L, Adeleke VT, Fatoba AJ, Adeniyi AA, Tshilwane SI, Adeleke MA, Maharaj R, Okpeku M
Reference: 
Infect Genet Evol. 2021 Apr 24:104875

Plasmodium falciparum (P. falciparum) is a leading causative agent of malaria, an infectious disease that can be fatal. Unfortunately, control measures are becoming less effective over time. A vaccine is needed to effectively control malaria and lead towards the total elimination of the disease. There have been multiple attempts to develop a vaccine, but to date, none have been certified as appropriate for wide-scale use. In this study, an immunoinformatics method is presented to design a multi-epitope vaccine construct predicted to be effective against P. falciparum malaria.

Baseline incidence of meningitis, malaria, mortality and other health outcomes in infants and young sub-Saharan African children prior to the introduction of the RTS,S/AS01E malaria vaccine

April 28, 2021 - 15:45 -- Open Access
Author(s): 
The RTS,S Epidemiology EPI-MAL-002 Study Group
Reference: 
Malaria Journal 2021 20:197, 26 April 2021

The lack of background disease incidence rates in sub-Saharan countries where the RTS,S/AS01E malaria vaccine is being implemented may hamper the assessment of vaccine safety and effectiveness. This study aimed to document baseline incidence rates of meningitis, malaria, mortality, and other health outcomes prior to vaccine introduction through the Malaria Vaccine Implementation Programme.

Pages

Subscribe to RSS - vaccine